About
Current Health provides the clinical and operational infrastructure needed to bring advanced therapies and complex care closer to patients. Its AI-enabled remote management technology supports health systems, community practices, and life sciences companies in safely scaling programs like CAR-T cell therapy, bispecific antibodies, and hospital-at-home initiatives—reducing inpatient bed dependency while maintaining rigorous clinical oversight. The platform offers four core models: High-Acuity Care at Home for launching and scaling home-based clinical programs; Advanced Therapies for Health Systems to deliver outpatient CAR-T and bispecific therapies while optimizing 340B benefits; Advanced Therapies for Community Practices with turnkey FACT and payer negotiation support; and Life Sciences services including 24/7 pharmacovigilance, decentralized clinical trial (DCT) infrastructure, and real-world evidence (RWE) generation for Phase I–IV trials. Real-world outcomes demonstrate its effectiveness: Sarah Cannon Cancer Institute shifted 90%+ of CAR-T therapies to outpatient settings, saving 1,200 bed days in the first 100 patients, while Mass General Brigham operates one of the nation's largest Hospital at Home programs averaging 49 patients daily with a low readmission rate. Current Health is trusted by leading healthcare organizations seeking to extend clinical reach, improve patient experiences, and optimize operational efficiency through intelligent, technology-enabled care delivery beyond traditional hospital settings.
Key Features
- AI-Enabled Remote Patient Monitoring: Continuous, real-time monitoring of patients receiving high-acuity or advanced therapy care outside the hospital, with AI-driven alerts and clinical data documentation.
- Advanced Therapy Outpatient Infrastructure: Turnkey clinical and operational support for delivering CAR-T and bispecific therapies in outpatient, community, and home settings without inpatient bed dependency.
- Hospital at Home Programs: Proven operational framework for launching and scaling hospital-at-home programs with clinical safety protocols, staffing coordination, and technology integration.
- Life Sciences & Decentralized Clinical Trials: 24/7 pharmacovigilance, DCT infrastructure, and robust real-world evidence generation supporting Phase I–IV clinical trials for advanced therapy pipelines.
- Payer Negotiation & 340B Optimization: Support for community practices and health systems to navigate payer contracting, FACT accreditation, and 340B program optimization for advanced therapies.
Use Cases
- Health systems shifting CAR-T cell therapy and bispecific antibody administration from inpatient to outpatient or home settings to reduce bed utilization and improve patient experience
- Community hospitals and physician groups building turnkey infrastructure to offer advanced oncology therapies with FACT accreditation and payer contracting support
- Large health systems launching or scaling hospital-at-home programs with proven clinical safety protocols and AI-driven remote monitoring
- Life sciences companies running decentralized Phase I–IV clinical trials with 24/7 pharmacovigilance and real-world evidence generation
- Healthcare organizations seeking to extend clinical reach into home and community settings while maintaining rigorous safety and quality standards for complex patients
Pros
- Proven Real-World Outcomes: Documented results from major health systems like Sarah Cannon and Mass General Brigham demonstrate significant bed-day savings and successful outpatient therapy delivery at scale.
- End-to-End Clinical & Operational Support: Combines AI technology with specialized services—staffing, payer negotiation, FACT support—providing a comprehensive solution rather than just a software platform.
- Broad Care Model Coverage: Supports multiple care delivery models from hospital-at-home to community oncology practices and life sciences trials, making it versatile across the healthcare ecosystem.
Cons
- Enterprise-Only Pricing: Designed exclusively for large health systems, community hospitals, and life sciences companies—not accessible to individual providers or small practices without significant infrastructure.
- Implementation Complexity: Deploying advanced therapy or hospital-at-home programs requires significant organizational alignment, staffing changes, and integration with existing clinical workflows.
Frequently Asked Questions
What types of organizations does Current Health serve?
Current Health serves health systems, community hospitals, physician groups, MSOs (management services organizations), and life sciences/pharma companies seeking to deliver complex care and advanced therapies outside traditional inpatient settings.
How does Current Health support CAR-T therapy delivery at home or in outpatient settings?
Current Health provides the clinical oversight technology, 24/7 remote monitoring, operational workflows, and staffing coordination needed to safely administer CAR-T and bispecific therapies in outpatient or home environments, reducing reliance on inpatient beds.
What is the Hospital at Home model offered by Current Health?
The Hospital at Home model provides patients with acute-level care in their homes using Current Health's remote monitoring technology and in-home clinical services, as demonstrated by Mass General Brigham's program which maintains an average daily census of 49 patients with a low readmission rate.
How does Current Health support life sciences and clinical trials?
Current Health offers decentralized clinical trial (DCT) infrastructure, 24/7 pharmacovigilance, and real-world evidence (RWE) generation capabilities to support Phase I–IV clinical trials for advanced therapy developers.
What AI capabilities does Current Health's platform include?
The platform uses AI-enabled remote management technology to continuously monitor patient vitals and clinical status, surface actionable data to care teams in near real-time, and document changes—enabling faster clinical decisions and safer remote care delivery.
